ABSTRACT
We recently performed 568 rapid neutralizing antibody (NAb) tests on 164 fully vaccinated individuals who received either Moderna or Pfizer COVID-19 vaccine regimens over 7 weeks. The NAb levels against the wild type (WA1/2020), Delta, and Kappa variants were measured and compared. Depending on each individuals medical condition and vaccination status, the NAb levels for most of the fully vaccinated people decreased within 2-6 months, while a small number of individuals either generated non-detectable amount of NAbs after full vaccination (e.g., immunocompromised), or had high NAb levels lasting beyond 6 months. Since the NAb levels vary significantly among different individuals and decrease over time, the deployment of a low-cost rapid test to monitor NAb levels against both the wild type and emerging variants among fully vaccinated individuals can play a very crucial role to control the current pandemic. Our study provides an example of using such a rapid NAb test to fill this currently unmet medical need.
ABSTRACT
Objective: To optimize matrix composition and technology for Jiefushuang Emulsion. Methods: Orthogonal design was used, oil phase, agitation velocity, emulsifiers and emulsify temperature were selected as variable factors. Results: The optimum matrix composition and technology were: The ratio of oil to water was 2∶3, emulsifiers: 320g(oil 500mL), HLB: 15, emulsity temperature: 70?C , agitation velocity: 800 revolutions per minute, lasting for 20 minutes. Conclusion: The emulsion prepared accords with the stipulation of the appendix of Chinese pharmacopoeia (2000).
